| QR CODE |
POSTER ID |
POSTER |
| 0116 |
P1.1. |
Central effects of botulinum Toxin A Recovery of spinal inhibition after botulinum toxin A in stroke patients |
| 0050 |
P1.2. |
Using the muscle force test in the monkey to measure biological activity of botulinum neurotoxins |
| 0013 |
P1.3. |
Validation of the “BINACLE” (Binding and Cleavage) Assay for the In Vitro Safety Testing of Tetanus Vaccines |
| 0085 |
P1.7. |
Botulinum Neurotoxin Type A–Cleaved SNAP25 Is Confined to Primary Motor Neurons and Localized on the Plasma Membrane Following Intramuscular Toxin Injection |
| 0117 |
P1.8. |
BIOLOGICAL TOXINS DETECTION: A RAPID DIAGNOSIS IN AN EMERGENCY RESPONSE |
| 0061 |
P1.10. |
Augmentation of the catalytic activity of Botulinum Neurotoxin Type B does not result in increased potency in physiological systems |
| 0064 |
P1.11. |
HPLC analysis of recombinant Botulinum neurotoxins: expanding the analytical toolbox |
| 0032 |
P1.12. |
Use of high-content imaging in botulinum toxin research |
| 0063 |
P1.13. |
Mechanisms of intestinal absorption of botulinum neurotoxin comples |
| 0046 |
P1.14. |
Purification and characterisation of recombinant botulinum neurotoxin serotype FA, also known as serotype H |
| 0040 |
P1.16. |
An evaluation of the cGMP manufacturing process economics and high-throughput characterisation of Targeted Secretion Inhibitors |
| 0041 |
P1.17. |
Recombinant Botulinum neurotoxin serotype A1 (SXN102342): protein engineering and process development |
| 0019 |
P1.20. |
rBoNT/A mutants with polypeptide extension show different kinetic properties |
| 0049 |
P1.21. |
SXN102342, a novel, recombinant botulinum neurotoxin type A1: in vivo characterization |
| 0037 |
P1.24. |
Rational modification of botulinum neurotoxin by directed scanning mutagenesis |
| 0110 |
P1.25. |
THE FIRST CASE OF TYPE F BOTULISM, IN PORTUGAL |
| 0020 |
P1.26. |
Light-chain-modified rBoNT/A mutants with improved stability |
| 0048 |
P1.27. |
An innovative solution to the unique challenges in manufacturing recombinant botulinum neurotoxins |
| 0038 |
P1.28. |
Human and mouse isolated bladder preparations are not equally affected by botulinum neurotoxin serotypes A and B |
| 0043 |
P1.32. |
SNARE complexes mediate TNFα-induced co-trafficking of TRPV1 and TRPA1 on pain peptide-containing vesicles to the surface of sensory neurons |
| 0021 |
P1.34. |
Design of modified botulinum toxin A variants with a shorter persistence of paralysis |
| 0022 |
P1.35. |
Properties of a chimeric BoNT/A1–A4 |
| 0109 |
P1.36. |
NT401 (FasTox): a novel, rapid, and short-acting modified botulinum neurotoxin |
| 0033 |
P1.37. |
Informed manufacturing process development of a recombinant botulinum neurotoxin through the use of a sensitive and reproducible sandwich ELISA |
| 0121 |
P1.39. |
CENTRAL IMMEDIATE EFFECT OF BOTULINUM TOXIN THERAPY OF GENERALIZED SPASTICITY |
| 0094 |
P1.46. |
GANGLIOSIDE RECEPTOR RECOGNITION BY BOTULINUM NEUROTOXIN A |
| 0093 |
P2.1. |
STRUCTURAL CHANGES OF CORTICAL THICKNESS AFTER BOTULINUM TOXIN TREATMENT (BONT) ASSOCIATED TO MOTOR RE-LEARNING TECHNIQUES (MRT) IN PATIENTS WITH CERVICAL DYSTONIA (CD). A LONGITUDINAL NEUROIMAGING STUDY. |
| 0086 |
P2.3. |
DURATION OF THE CLINICAL EFFECT OF BOTULINUM TOXIN IN FOCAL DYSTONIAS |
| 0002 |
P2.6. |
Sensory Trick: Infiltration of its Trigger Point with Botulinum Neurotoxin in Cervical Dystonia |
| 0008 |
P2.7. |
Predictors of OnabotulinumtoxinA Treatment Response in Patients with Cervical Dystonia |
| 0024 |
P2.8. |
Treatment of camptocormia in patients with Parkinson’s disease by injecting incobotulinumtoxin A (Xeomin®) |
| 0072 |
P2.9. |
Efficacy and Safety of a 2 mL Dilution of AbobotulinumtoxinA Compared With Placebo in Adult Patients With Cervical Dystonia |
| 0045 |
P2.12. |
PRETARSAL BLEPHAROSPASM: CLINICAL, ELECTROMIOGRAPHIC FEATURES AND LONG TERM TREATMENT WITH BOTULINUM TOXIN |
| 0065 |
P2.14. |
Clinical Characteristics of Oromandibular Dystonia: a Multicenter Review of 201 Cases |
| 0096 |
P2.15. |
Comparison of Methodology, Patient Characteristics, and Treatment Results from ANCHOR-CD (AbobotulinumtoxinA Neurotoxin: Clinical and Health Economics Outcomes Registry in Cervical Dystonia) and Other Registry Studies of Bolulinum Toxin Type A in Cervical Dystonia |
| 0026 |
P2.16. |
TRANSORAL ADMINISTRATION OF INCOBOTULINUMTOXIN A FOR THE MANAGEMENT OF LARYNGEAL DYSTONIA |
| 0111 |
P2.18. |
A randomized, double-blind, placebo-controlled trial on the efficacy and safety of incobotulinumtoxinA (Inco/A) for essential tremor using kinematics-guided clinical decision support |
| 0010 |
P3.1. |
CONTRAST-ENHANCED ULTRASOUND ASSESSMENT OF THE MICROCIRCULATION OF SPASTIC CALF MUSCLES PRIOR TO BOTULINUM TOXIN TYPE A INJECTION IN PATIENTS WITH LONG-STANDING LOWER LIMB SPASTICITY (INITIAL EXPERIENCE) |
| 0014 |
P3.2. |
INTEGRATED MANAGEMENT OF UPPER-LIMB SPASTICITY WITH BOTULINUM TOXIN TYPE A INJECTIONS AND KINESIO TAPING |
| 0104 |
P3.3. |
Efficacy of incobotulinumtoxinA (Xeomin®) in treatment of lower-limb spasticity, including pes equinovarus, in adults |
| 0126 |
P3.5. |
OUTCOME OF A MULTILEVEL BoNTA TREATMENT, WHEN INCLUDING SHOULDER MUSCLES, USING PATIENT-CENTERED GOAL ATTAINMENT |
| 0127 |
P3.6. |
RELEVANCE AND IMPACT OF INCLUDING SHOULDER MUSCLES IN TREATMENT OF POST-STROKE UPPER LIMB SPASTICITY |
| 0113 |
P3.7. |
ARE THERE DIFFERENCES IN MOST FREQUENTLY INJECTED MUSCLES IN UPPER, LOWER AND UPPER + LOWER LIMBS, REGARDING THE TREATMENT GOAL AREAS? AN OVERVIEW OF REAL-LIFE CLINICAL PRACTICE IN A REFERENCE SPASTICITY CLINIC |
| 0025 |
P3.9. |
EFFICACY AND SAFETY OF INCOBOTULINUMTOXINA (XEOMIN®) IN THE TREATMENT OF SEVERE MUSCLE SPASTICITY FOLLOWING TRAUMATIC BRAIN INJURY: A CASE REPORT |
| 0098 |
P3.10. |
Botulinum toxin treatment for spasticity: clinical experience with changing from abobotulinumtoxinA (Dysport®) to incobotulinumtoxinA (Xeomin®) |
| 0051 |
P3.11. |
Correlations between reduced spasticity, goal attainment and global assessment of benefits in patients with upper limb spasticity treated with botulinum toxin A |
| 0097 |
P3.12. |
Switching botulinum toxin formulations from onabotulinumtoxinA (Botox®) to incobotulinumtoxinA (Xeomin®): experience from a spasticity outpatient clinic |
| 0073 |
P3.13. |
Phase 3 Trial to Evaluate AbobotulinumtoxinA (Dysport®) Injections in Children with Upper Limb Spasticity due to Cerebral Palsy: A Study Design |
| 0047 |
P3.14. |
AbobotulinumtoxinA (Dysport®) injection doses per muscle in paediatric patients with lower limb spasticity |
| 0114 |
P3.15. |
Time to retreatment after abobotulinumtoxinA (Dysport®) injections in children with dynamic equinus foot deformity |
| 0066 |
P3.17. |
A DESCRIPTIVE ANALYSIS OF TREATMENT GOALS IN A LARGE POST-STROKE OUTPATIENT POPULATION REFLECTED BY THE ROUTINE PRACTICE OF A REFERENCE SPASTICITY CLINIC |
| 0088 |
P3.19. |
EFFECTIVENESS OF BOTULINUM TOXIN TYPE A (BONT-A) IN LONG-TERM TREATMENT OF HEREDITARY SPASTIC PARAPLEGIA IN CHILDREN: REVIEW OF A SERIES OF 63 CASES |
| 0074 |
P3.21. |
IS FUNCTIONAL IMPROVEMENT THE SAME IN STROKE PATIENTS TREATED WITH BOTULINUM TOXIN IN UPPER LIMB ONLY VS A TYPICAL POSTSTROKE INPATIENT POPULATION IN A NEUROREHABILITATION SERVICE? |
| 0076 |
P3.22. |
POSTSTROKE UPPER LIMB SPASTICITY TREATMENT INCLUDING BOTULINUM TOXIN IN AN INPATIENT POST-ACUTE REHABILITATION PROGRAM: HOW ARE WE DOING IT? |
| 0081 |
P3.23. |
TREATMENT PROGRAMS INCLUDING BOTULINUM TOXIN, TREATMENT GOALS, AND GOAL ACHIEVMENT FOR POSTSTROKE SPASTICITY: DOES TIME MATTER? |
| 0053 |
P3.24. |
Duration of effect of abobotulinumtoxinA (Dysport®) in adult patients with lower limb spasticity post stroke or traumatic brain injury |
| 0054 |
P3.25. |
Duration of effect of abobotulinumtoxinA (Dysport®) in adult patients with upper limb spasticity (ULS) post stroke or traumatic brain injury |
| 0099 |
P3.25. |
Sustained incobotulinumtoxinA (Xeomin®) efficacy in upper-limb post-stroke spasticity over 48 weeks in a Phase 3, placebo-controlled study with an open-label extension |
| 0052 |
P3.26. |
Improvement of active movement and function in adults with chronic spastic paresis following repeated treatment with abobotulinumtoxinA (Dysport®) |
| 0100 |
P3.27. |
SPAsticity in PractiCE (SPACE) – an international, observational study of botulinum toxin type A in spasticity |
| 0036 |
P3.28. |
Effectiveness and safety assessment of IncobotulinumtoxinA (XEOMIN®) injections in the lower-limb muscles of young, low-weight children with cerebral palsy |
| 0082 |
P3.29. |
BOTULINUM TOXIN TYPE A – DOSES FOR 3 DIFFERENT FORMULATIONS: A REAL-LIFE PRACTICE EXPERIENCE IN POSTSTROKE SPASTICITY TREATMENT |
| 0055 |
P3.30. |
Relationship between abobotulinumtoxinA injections into shoulder muscles and patient-centred primary goal selection and achievement: sub-analyses from the Upper Limb International Spasticity (ULIS)-II Study |
| 0075 |
P3.31. |
THE IMPACT ON GAIT FUNCTIONALITY OF UPPER LIMB BOTULINUM TOXIN TREATMENT WITHIN AN INPATIENT REHABILITATION PROGRAM |
| 0044 |
P3.32. |
INFLUENCE OF THE TIME INTERVAL BETWEEN INJECTIONS ON THE EFFICACY OF INCOBOTULINUMTOXINA (XEOMIN) FOR UPPER LIMB SPASTICITY: A PRELIMINARY STUDY |
| 0108 |
P3.33. |
Duration of treatment effect of incobotulinumtoxinA (Xeomin®) in upper-limb spasticity |
| 0106 |
P3.34. |
IncobotulinumtoxinA (Xeomin®) sustainably improves upper-limb spasticity – pooled analysis of two Phase 3 trials |
| 0056 |
P3.36. |
A comparison of goal selection and achievement according to patient sex in the Upper Limb International Spasticity (ULIS)-II study |
| 0016 |
P3.37. |
ANALYSIS OF TOTAL DOSAGES AND INTERVALS BETWEEN THE REPEATED ABOBOTULINUMTOXIN A INJECTIONS IN CHILDREN WITH SPASTIC CEREBRAL PALSY: MULTICENTRAL RUSSIAN STUDY |
| 0017 |
P3.38. |
EVALUATION OF GOALS FOR BOTULINUM TOXIN TREATMENT DIRECTED TO POST STROKE SPASTICITY DURING 10 INJECTIONS |
| 0115 |
P3.39. |
THERAPEUTIC BENEFIT OF BOTULINUM TOXIN A FOR SPASTICITY OF THE TRICEPS SURAE IN PATIENTS WITH MULTIPLE SCLEROSIS: AN OBSERVATIONAL STUDY ON GAIT SPATIOTEMPORAL PARAMETERS |
| 0028 |
P3.40. |
CLINICAL PRACTICE WITH INCOBOTULINUMTOXINA (XEOMIN®) IN THE TREATMENT OF SPASTICITY IN CHILDREN WITH CEREBRAL PALSY |
| 0027 |
P3.41. |
EFFECTIVENESS AND PATIENT SATISFACTION WITH INCOBOTULINUMTOXIN A (XEOMIN®) FOR THE TREATMENT OF LOWER LIMB SPASTICITY IN MULTIPLE SCLEROSIS |
| 0057 |
P3.42. |
A comparison of goal selection and achievement between botulinum toxin A (BoNT-A) naïve and non-naïve patients in the Upper Limb International Spasticity (ULIS)-II study |
| 0009 |
P3.43. |
Botulinum neurotoxin injection techniques for the treatment of limb spasticity: a systematic review |
| 0007 |
P3.44. |
Impact of Early Intervention With OnabotulinumtoxinA Treatment in Adult Patients With Post-Stroke Lower Limb Spasticity |
| 0112 |
P3.45. |
DEFINING PATIENT-CENTRED GOALS IN BOTULINUM TOXIN POST–STROKE SPASTICITY DO TREATED REGIONS MATTER? |
| 0077 |
P3.46. |
HOW WE MANAGE POST-STROKE SPASTICITY IN OUTPATIENT CLINICS: 16 YEAR EXPERIENCE OF A REFERENCE CENTER |
| 0034 |
P3.47. |
An international, multicenter, prospective, randomized, evaluator-blinded study comparing different botulinum toxin injection strategies for treatment of upper limb spasticity |
| 0103 |
P3.48. |
Long-term effects of high doses of incobotulinumtoxinA (Xeomin®) for treatment of spasticity |
| 0058 |
P3.50. |
Baseline characteristics of patients from a pilot study to assess the effect of early use of abobotulinumtoxin-A (Dysport®) in spasticity progression post stroke |
| 0067 |
P3.52. |
Assessment of botulinum toxin treatment in pediatric cerebral palsy patients in the United States managed Medicaid population |
| 0118 |
P3.53. |
BOTULINUM TOXIN AND MIRROR THERAPY: A NEW APPROACH FOR POSTSTROKE SPASTICITY |
| 0102 |
P3.54. |
Increasing doses of incobotulinumtoxinA (Xeomin®; 400–800 U) improve the functional impact of upper-limb spasticity |
| 0089 |
P3.55. |
FLEXIBLE INTERVALS FOR BOTULINUM TOXIN A INJECTIONS IN DISABLING SPASTICITY |
| 0059 |
P3.56. |
Integrated upper limb spasticity management including botulinum toxin A on patient-centred goal attainment: methodology for ULIS-III and initial goal-setting data |
| 0042 |
P3.57. |
Improvement in poststroke upper limb spasticity patterns after treatment with Botulinum toxin A: A prospective observational study |
| 0105 |
P3.58. |
Efficacy of incobotulinumtoxinA (Xeomin®) in the treatment of shoulder spasticity due to cerebral causes |
| 0101 |
P3.59. |
Prospective, single-arm, dose-titration study of incobotulinumtoxinA (Xeomin®; up to 800 U) for treatment of upper- and lower-limb spasticity |
| 0091 |
P3.60. |
COHORT OF POST STROKE SPASTIC HEMIPLEGIC PATIENTS USING BOTULINUM TOXIN TYPE A FROM 2004 TO 2016 |
| 0078 |
P3.61. |
BOTULINUM TOXIN TREATMENT FOR POST STROKE SPASTICITY: DO THE GOALS OF TREATMENT CHANGE OVER TIME |
| 0092 |
P3.62. |
Improvement of spasticity following abobotulinumtoxinA (Dysport®) injections in shoulder muscles in hemiparetic patients with upper limb spasticity – Sub-analysis of a prospective, long-term, open-label study with single and repeated injection cycles |
| 0071 |
P5.2. |
Safety and Tolerability of OnabotulinumtoxinA in the Treatment of Facial Lines: Statistical Meta-analysis of Pooled Data From Global Registration Studies of Treatment of Crow’s Feet Lines and Glabellar Lines in More Than 3900 Participants |
| 0068 |
P5.3. |
OnabotulinumtoxinA in the Treatment of Crow’s Feet Lines in Japanese Subjects |
| 0070 |
P5.4. |
Safety and Efficacy of OnabotulinumtoxinA in the Treatment of Crow’s Feet Lines and Glabellar Lines in Japanese Subjects |
| 0069 |
P5.5. |
Safety and Efficacy of OnabotulinumtoxinA for the Treatment of Crow’s Feet Lines in Chinese Subjects |
| 0001 |
P6.1. |
Anatomical look into OnabotulinumtoxinA injection for chronic migraine headache |
| 0004 |
P6.2. |
Efficacy and Safety of OnabotulinumtoxinA in an Open-Label Study for the Prophylactic Treatment of Chronic Migraine in Adult Patients: COMPEL |
| 0011 |
P6.3. |
EFFICACY OF FLEXIBLE INCOBOTULINUMTOXINA TREATMENT INTERVALS IN A PATIENT WITH MYOFASCIAL PAIN IN UPPER CROSS SYNDROME |
| 0035 |
P6.4. |
Results of a New Botox Injection Paradigm for Treatment of Migraines: Anatomical, Regional, and Targeted (ART) |
| 0005 |
P6.5. |
OnabotulinumtoxinA for Chronic Migraine in Korea: 1-Month Post-Marketing Surveillance and Phase 4 Trial Results |
| 0006 |
P6.7. |
Real-World Utilization and Safety of OnabotulinumtoxinA for Chronic Migraine from an Observational Study in the European Union |
| 0030 |
P6.8. |
Administration of Neurotoxin-Disport as principal new approach to therapy of complicated forms of migraine |
| 0083 |
P6.9. |
Botulinum Toxin Type A Infiltration for Primary Headache Syndrome Post-Intracerebral Hemorrhage. A Case Report |
| 0015 |
P6.10. |
Long-term effficacy of ultrasound-guided injection of incobotulinumtoxinA (XEOMIN®) in piriformis syndrome |
| 0012 |
P6.11. |
An integrated approach to the treatment of temporo-mandibular disorder with severe pain syndrome. |
| 0090 |
P6.12. |
ROLE OF CORTICAL EXCITABILITY IN CHRONIC MIGRAINE PREVENTION: A STUDY DESIGN FOR A RANDOMIZED OPEN-LABEL TRIAL |
| 0003 |
P7.1. |
INCOBOTULINUMTOXINA (XEOMIN) TREATMENT FOR THE CORRECTION OF MIMIC MUSCLE FUNCTION AFTER FACIAL NERVE INJURY |
| 0023 |
P7.2. |
SKETCHING VIDEO GRABS FRAMES TO ASSESS GAIT IMPROVEMENT |
| 0125 |
P7.3. |
BOTULINUM TOXIN B IN THE TREATMENT OF POSTMENOPAUSAL CRANIOFACIAL HYPERHIDROSIS |
| 0018 |
P7.9. |
A Region Specific Technique To Quantify The Degree of Botulinum Muscle Diffusion Using Magnetic Resonance Imaging |
| 0060 |
P7.10. |
ABOBOTULINUM TOXIN-A PROSPECTIVE RANDOMIZED DOUBLE-BLIND MULTICENTER STUDY FOR DEGENERATIVE COXARTHROSIS |
| 0107 |
P7.12. |
Efficacy of a 4:1 dose ratio in patients switching botulinum toxin formulation from abobotulinumtoxinA to incobotulinumtoxinA |
| 0087 |
P7.13. |
BOTULINUM TOXIN INJECTIONS CAN PREVENT EARLY RELAPSE AFTER GIANT ABDOMINAL WALL SURGERY |
| 0039 |
P7.17. |
An innovative international educational network to improve physicians’ current management practices for cervical dystonia and spasticity |
| 0062 |
P7.18. |
Practical Management of Flu-like Symptoms Among Patients Receiving Botulinum Toxin Injections |
| 0031 |
P7.19. |
BOTULINUM TOXIN AND ANTICHOLINERGICS IN THE TREATMENT OF COMPENSATORY HYPERHIDROSIS AFTER SYMPATHECTOMY |
| 0123 |
P7.19. |
BOTULINUM TOXIN AND ANTICHOLINERGICS IN THE TREATMENT OF COMPENSATORY HYPERHIDROSIS AFTER SYMPATHECTOMY |
| 0122 |
P7.22. |
EFFECT OF INCOBOTULINUM TOXIN-A (XEOMIN®) FOR THE TREATMENT OF OBSTRUCTIVE AND FUNCTIONAL EPIPHORA: A SHORT-TERM PILOT STUDY |
| 0124 |
P7.23. |
HYPERHIDROSIS IN CHILDREN: A RETROSPECTIVE STUDY DESCRIBING SYMPTOMS, CONSEQUENCES, AND TREATMENT WITH BOTULINUM TOXIN TYPES A AND B |
| 0029 |
P7.24. |
TEMPOROMANDIBULAR DISORDERS TREATED SUCCESSFULLY WITH INCOBOTULINUMTOXINA |
| 0095 |
P7.28. |
Sensitivity of the extensor digitorum brevis and Minor’s starch-iodine tests at detecting dose-effects of Dysport® in male healthy volunteers |
| 0084 |
P7.30. |
Two-step Approach with OnabotulinumtoxinA: Intradermal & Intramuscular Infiltrations for T8-T12 Chronic Post Herpetic Neuralgia: A Case Report |
Click here to sign up, and then manage your subscription.